medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-7-30-33medsovet-596Research ArticleЭндокринологияEndocrinologyДиабетическая макроангиопатия и самоконтроль гликемииDiabetic macroangiopathy and self-monitoring of glucoseФедороваО. С.FedorovaOSnoemail@neicon.ruFederal Bureau of Medical and Social Examination, Russia's Ministry of LabourRussian Federation201430122014073033Copyright © Федорова О.С., 20142014Федорова О.С.Fedorova O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/596

Диабетическая макроангиопатия - генерализованное атеросклеротическое поражение артерий крупного и среднего калибра при сахарном диабете (СД). Макрососудистые осложнения при сахарном диабете, приводящие к сердечно-сосудистым заболеваниям (ССЗ), являются главной причиной смерти больных СД. ССЗ в меньшей степени, чем микрососудистые осложнения, зависят от гипергликемии или интенсивности снижения гликемии. В то же время существуют крупные работы, подтверждающие данную взаимосвязь. К диабетическим макроангиопатиям относятся: ишемическая болезнь сердца (ИБС), -- цереброваскулярная болезнь (ЦВБ), хронические облитерирующие заболевания периферических артерий [1].

Diabetic macroangiopathy is a general term for atherosclerotic vascular diseases of large- and medium-caliber arteries in diabetes mellitus (DM). Macrovascular complications of diabetes leading to cardiovascular diseases (CVD) are the major cause of death in patients with diabetes. CVD are less dependent on hyperglycemia or the rate of glucose lowering than microvascular complications. At the same time, there are big research works confirming this relationship. Diabetic macroangiopathies include coronary heart disease (CHD), cerebrovascular disease (CVD), chronic obliterating peripheral arterial diseases [1].

диабетическая макроангиопатиясердечно-сосудистые заболеванияинсулинотерапиясамоконтрольКонтур ТСdiabetic macroangiopathycardiovascular diseasesinsulin therapyself-monitoringContour TSReferencesАлгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. Вып. 6. Минздравсоцразвития РФ. М., 2013.Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. Вып. 6. Минздравсоцразвития РФ. М., 2013.Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353: 2643-2653.Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353: 2643-2653.Nathan DM, Zinman B, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years'duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005). Arch Intern Med, 2009, 169: 1307-1316.Nathan DM, Zinman B, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years'duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005). Arch Intern Med, 2009, 169: 1307-1316.Standards of Medical Care in Diabetes - 2014. American Diabetes Association. Diabetes Care, 2014, Jan., 37: S14-S80; doi:10.2337/dc14-S014.Standards of Medical Care in Diabetes - 2014. American Diabetes Association. Diabetes Care, 2014, Jan., 37: S14-S80; doi:10.2337/dc14-S014.Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-1589.Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-1589.Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358: 2545-2559.Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358: 2545-2559.Riddle MC, Ambrosius WT, Brillon DJ, et al. Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care, 2010, 33: 983-990.Riddle MC, Ambrosius WT, Brillon DJ, et al. Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care, 2010, 33: 983-990.Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009, 360: 129-139.Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009, 360: 129-139.DuckworthWC, Abraira C, Moritz TE, et al. Investigators of the VADT. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications, 2011, 25: 355-361.DuckworthWC, Abraira C, Moritz TE, et al. Investigators of the VADT. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications, 2011, 25: 355-361.Turnbull FM, Abraira C, Anderson RJ, et al. Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia, 2009, 52: 2470]. Diabetologia, 2009, 52: 2288-2298.Turnbull FM, Abraira C, Anderson RJ, et al. Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia, 2009, 52: 2470]. Diabetologia, 2009, 52: 2288-2298.Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med, 2011, 154: 554-559.Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med, 2011, 154: 554-559.

The authors declare that there are no conflicts of interest present.